enfortumab vedotin + pembrolizumab
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic Malignant Solid Tumors
Conditions
Locally Advanced or Metastatic Malignant Solid Tumors
Trial Timeline
Mar 9, 2020 → Sep 30, 2026
NCT ID
NCT04225117About enfortumab vedotin + pembrolizumab
enfortumab vedotin + pembrolizumab is a phase 2 stage product being developed by Astellas Pharma for Locally Advanced or Metastatic Malignant Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT04225117. Target conditions include Locally Advanced or Metastatic Malignant Solid Tumors.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced or Metastatic Malignant Solid Tumors were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07475806 | Phase 2 | Recruiting |
| NCT06906822 | Phase 2 | Recruiting |
| NCT06809140 | Phase 2 | Recruiting |
| NCT06470282 | Phase 1/2 | Recruiting |
| NCT05756569 | Phase 2 | Recruiting |
| NCT05239624 | Phase 2 | Recruiting |
| NCT04225117 | Phase 2 | Active |
Competing Products
20 competing products in Locally Advanced or Metastatic Malignant Solid Tumors